Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $3.7 billion of committed capital.
Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $3.7 billion of committed capital.
Secura Bio Announces $145 Million Financing Led By Athyrium Capital Management
Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
Kala Pharmaceuticals Announces Statistically Significant Results in STRIDE 3 Clinical Trial Evaluating EYSUVIS™
Asahi Kasei Completes Acquisition of Veloxis Pharmaceuticals Inc.
Lilly Announces Agreement to Acquire Dermira
HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events
Amryt Pharma plc Announces Completion of the Acquisition of Aegerion Pharmaceuticals, Inc.
We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Privacy Policy. By closing this message box or continuing to use our website you consent to our use of cookies.
